XML 46 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-based Compensation (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Activity Under Restricted Stock Units

Restricted Stock Units

 

 

 

Number of Units
 (in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2023

 

 

6,933

 

 

$

2.46

 

Assumed through acquisition

 

 

2,970

 

 

 

2.00

 

Granted

 

 

10,263

 

 

 

2.21

 

Vested

 

 

(4,002

)

 

 

2.34

 

Forfeited

 

 

(1,728

)

 

 

2.30

 

Balance at September 30, 2024

 

 

14,436

 

 

$

2.24

 

Schedule of Activity Under Stock Options

Stock Options

 

 

 

Number of
Options (in thousands)

 

 

Weighted-Average
Exercise Price
per Option

 

 

Weighted-
Average Remaining Contractual Life (in years)

 

 

Aggregate
Intrinsic
Value
(1) (in thousands)

 

Balance at December 31, 2023

 

 

9,294

 

 

$

3.62

 

 

 

8.5

 

 

 

 

Assumed through acquisition

 

 

28,184

 

 

 

4.80

 

 

 

 

 

 

 

Granted

 

 

6,697

 

 

 

2.50

 

 

 

 

 

 

 

Exercised

 

 

(573

)

 

 

2.12

 

 

 

 

 

 

 

Cancelled

 

 

(3,374

)

 

 

3.92

 

 

 

 

 

 

 

Balance at September 30, 2024

 

 

40,228

 

 

$

4.26

 

 

 

6.2

 

 

$

196

 

Vested at September 30, 2024

 

 

28,006

 

 

$

4.76

 

 

 

5.1

 

 

$

93

 

Unvested options at September 30, 2024

 

 

12,222

 

 

$

3.10

 

 

 

8.7

 

 

$

103

 

 

Aggregate intrinsic value as of September 30, 2024 was calculated as the difference between the closing price per share of the Company’s common stock on The Nasdaq Global Select Market on September 30, 2024, which was $1.93, and the exercise price of the options, multiplied by the number of in-the-money options.
Schedule of Nonvested Performance-Based Units Activity

Activity under the performance-based awards was as follows:

 

 

 

Number of Units
(in thousands)

 

 

Weighted-Average
Grant Date Fair Value per Unit

 

Balance at December 31, 2023

 

 

309

 

 

$

2.42

 

PSU granted

 

 

100

 

 

 

2.25

 

Performance adjustment

 

 

(26

)

 

 

2.42

 

PSU released

 

 

(383

)

 

 

2.38

 

Balance at September 30, 2024

 

 

 

 

$

 

 

Schedule of Stock-Based Compensation Expense

As of September 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

 

 

 

Securities To Be Issued Upon Exercise Of Options

 

 

Securities To Be Issued Upon Release Of Restricted Stock

 

 

Number Of Remaining Securities Available For Future Issuance

 

2022 Inducement Equity Incentive Plan

 

 

7,320

 

 

 

898

 

 

 

454

 

2011 Equity Incentive Plan

 

 

7,929

 

 

 

12,781

 

 

 

23,584

 

2017 Inducement Award Plan

 

 

59

 

 

 

 

 

 

2

 

2017 Employee Stock Purchase Plan

 

 

 

 

 

 

 

 

1,379

 

SomaLogic Plans

 

 

24,920

 

 

 

757

 

 

 

 

Total common stock reserved for future issuance

 

 

40,228

 

 

 

14,436

 

 

 

25,419

 

 

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense is reported in the Company's condensed consolidated statement of operations as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Cost of product revenue

 

$

136

 

 

$

151

 

 

$

441

 

 

$

524

 

Cost of services revenue

 

 

228

 

 

 

37

 

 

 

455

 

 

 

122

 

Cost of collaboration and other revenue

 

 

 

 

 

 

 

 

1

 

 

 

2

 

Research and development expense

 

 

724

 

 

 

459

 

 

 

4,480

 

 

 

1,241

 

Selling, general and administrative expense

 

 

4,833

 

 

 

2,739

 

 

 

18,885

 

 

 

7,759

 

Total stock-based compensation expense

 

$

5,921

 

 

$

3,386

 

 

$

24,262

 

 

$

9,648